National Round The Clock Hot Line
1-888-365-4458(US)  44-808-111-0143(EU)
86-108-294-5717(AS)
go to cart
1 2 3 4 5

Email Subscribe


Your Position:Home > Medical > Medicine > 2018-2025 Metastatic Melanoma Drug Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

2018-2025 Metastatic Melanoma Drug Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

Goods_sn:ygz-gz3

Publishers:QYResearch

Numbers:Share

Price:

License: single license enterprise license

2018-2025 Metastatic Melanoma Drug Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

Hard Copy: 3600 USD
PDF Copy (single user): 3600 USD
Enterprise wide License: 7200 USD
Pages: 121
Tables and Figures: 152
Published Date: Apr 2018
Publisher: QYR Pharma & Healthcare Research Center
Contact: Tel: 1-6262952442; 86-10-82945717; Email: sales@qyresearch.com

Summary

This report studies the Metastatic Melanoma Drug market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Metastatic Melanoma Drug market by product type and application/end industries.

The global Metastatic Melanoma Drug market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially the United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Metastatic Melanoma Drug.

United States plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of XX.

Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Metastatic Melanoma Drug in these regions, from 2013 to 2025 (forecast), covering
    United States
    North America
    Europe
    Asia-Pacific
    South America
    Middle East and Africa

The major players in global and United States market, including
    Merck & Co., Inc.
    Merck KGaA
    Millennium Pharmaceuticals, Inc.
    Morphotek, Inc.
    NewLink Genetics Corporation
    Novartis AG
    Omeros Corporation
    Oncolytics Biotech Inc.
    OncoSec Medical Inc.
    Ono Pharmaceutical Co., Ltd.
    Pfizer Inc.
    Pharmis Biofarmaceutica, Lda.
    Philogen S.p.A.
    Plexxikon Inc.
On the basis of product, the market is primarily split into
    AGI-134
    ALT-801
    ALT-803
    AMG-232
    Others
On the basis on the end users/application, this report covers
    Hospital
    Clinic
    Others

Table of Contents

2018-2025 Metastatic Melanoma Drug Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
1 Methodology and Data Source
    1.1 Methodology/Research Approach
        1.1.1 Research Programs/Design
        1.1.2 Market Size Estimation
        1.1.3 Market Breakdown and Data Triangulation
    1.2 Data Source
        1.2.1 Secondary Sources
        1.2.2 Primary Sources
    1.3 Disclaimer

2 Metastatic Melanoma Drug Market Overview
    2.1 Metastatic Melanoma Drug Product Overview
    2.2 Metastatic Melanoma Drug Market Segment by Type
        2.2.1 AGI-134
        2.2.2 ALT-801
        2.2.3 ALT-803
        2.2.4 AMG-232
        2.2.5 Others
    2.3 Global Metastatic Melanoma Drug Product Segment by Type
        2.3.1 Global Metastatic Melanoma Drug Sales (K Pcs) and Growth (%) by Type (2013, 2017 and 2025)
        2.3.2 Global Metastatic Melanoma Drug Sales (K Pcs) and Market Share (%) by Type (2013-2018)
        2.3.3 Global Metastatic Melanoma Drug Revenue (Million USD) and Market Share (%) by Type (2013-2018)
        2.3.4 Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2013-2018)
    2.4 United States Metastatic Melanoma Drug Product Segment by Type
        2.4.1 United States Metastatic Melanoma Drug Sales (K Pcs) and Growth by Type (2013, 2017 and 2025)
        2.4.2 United States Metastatic Melanoma Drug Sales (K Pcs) and Market Share by Type (2013-2018)
        2.4.3 United States Metastatic Melanoma Drug Revenue (Million USD) and Market Share by Type (2013-2018)
        2.4.4 United States Metastatic Melanoma Drug Price (USD/Pcs) by Type (2013-2018)

3 Metastatic Melanoma Drug Application/End Users
    3.1 Metastatic Melanoma Drug Segment by Application/End Users
        3.1.1 Hospital
        3.1.2 Clinic
        3.1.3 Others
    3.2 Global Metastatic Melanoma Drug Product Segment by Application
        3.2.1 Global Metastatic Melanoma Drug Sales (K Pcs) and CGAR (%) by Application (2013, 2017 and 2025)
        3.2.2 Global Metastatic Melanoma Drug Sales (K Pcs) and Market Share (%) by Application (2013-2018)
    3.3 United States Metastatic Melanoma Drug Product Segment by Application
        3.3.1 United States Metastatic Melanoma Drug Sales (K Pcs) and CGAR (%) by Application (2013, 2017 and 2025)
        3.3.2 United States Metastatic Melanoma Drug Sales (K Pcs) and Market Share (%) by Application (2013-2018)

4 Metastatic Melanoma Drug Market Status and Outlook by Regions
    4.1 Global Market Status and Outlook by Regions
        4.1.1 Global Metastatic Melanoma Drug Market Size and CAGR by Regions (2013, 2017 and 2025)
        4.1.2 North America
        4.1.3 Asia-Pacific
        4.1.4 Europe
        4.1.5 South America
        4.1.6 Middle East and Africa
        4.1.7 United States
    4.2 Global Metastatic Melanoma Drug Sales and Revenue by Regions
        4.2.1 Global Metastatic Melanoma Drug Sales (K Pcs) and Market Share (%) by Regions (2013-2018)
        4.2.2 Global Metastatic Melanoma Drug Revenue (Million USD) and Market Share (%) by Regions (2013-2018)
        4.2.3 Global Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        4.2.4 North America Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        4.2.5 Europe Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        4.2.6 Asia-Pacific Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        4.2.7 South America Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
        4.2.8 Middle East and Africa Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        4.2.9 United States Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)

5 Global Metastatic Melanoma Drug Market Competition by Players/Manufacturers
    5.1 Global Metastatic Melanoma Drug Sales (K Pcs) and Market Share by Players (2013-2018)
    5.2 Global Metastatic Melanoma Drug Revenue (Million USD) and Share by Players (2013-2018)
    5.3 Global Metastatic Melanoma Drug Average Price (USD/Pcs) by Players (2013-2018)
    5.4 Global Top Players Metastatic Melanoma Drug Manufacturing Base Distribution, Sales Area, Product Types
    5.5 Metastatic Melanoma Drug Market Competitive Situation and Trends
        5.5.1 Metastatic Melanoma Drug Market Concentration Rate
        5.5.2 Global Metastatic Melanoma Drug Market Share (%) of Top 3 and Top 5 Players
        5.5.3 Mergers & Acquisitions, Expansion

6 United States Metastatic Melanoma Drug Market Competition by Players/Manufacturers
    6.1 United States Metastatic Melanoma Drug Sales (K Pcs) and Market Share by Players (2013-2018)
    6.2 United States Metastatic Melanoma Drug Revenue (Million USD) and Share by Players (2013-2018)
    6.3 United States Metastatic Melanoma Drug Average Price (USD/Pcs) by Players (2013-2018)
    6.4 United States Metastatic Melanoma Drug Market Share (%) of Top 3 and Top 5 Players


7 Metastatic Melanoma Drug Players/Manufacturers Profiles and Sales Data
    7.1 Merck & Co., Inc.
        7.1.1 Company Basic Information, Manufacturing Base and Competitors
        7.1.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.1.4 Main Business/Business Overview
    7.2 Merck KGaA
        7.2.1 Company Basic Information, Manufacturing Base and Competitors
        7.2.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.2.4 Main Business/Business Overview
    7.3 Millennium Pharmaceuticals, Inc.
        7.3.1 Company Basic Information, Manufacturing Base and Competitors
        7.3.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.3.4 Main Business/Business Overview
    7.4 Morphotek, Inc.
        7.4.1 Company Basic Information, Manufacturing Base and Competitors
        7.4.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.4.4 Main Business/Business Overview
    7.5 NewLink Genetics Corporation
        7.5.1 Company Basic Information, Manufacturing Base and Competitors
        7.5.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.5.4 Main Business/Business Overview
    7.6 Novartis AG
        7.6.1 Company Basic Information, Manufacturing Base and Competitors
        7.6.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.6.4 Main Business/Business Overview
    7.7 Omeros Corporation
        7.7.1 Company Basic Information, Manufacturing Base and Competitors
        7.7.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.7.4 Main Business/Business Overview
    7.8 Oncolytics Biotech Inc.
        7.8.1 Company Basic Information, Manufacturing Base and Competitors
        7.8.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.8.4 Main Business/Business Overview
    7.9 OncoSec Medical Inc.
        7.9.1 Company Basic Information, Manufacturing Base and Competitors
        7.9.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.9.4 Main Business/Business Overview
    7.10 Ono Pharmaceutical Co., Ltd.
        7.10.1 Company Basic Information, Manufacturing Base and Competitors
        7.10.2 Metastatic Melanoma Drug Product Category, Application and Specification
            7.10.2.1 Product A
            7.10.2.2 Product B
        7.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
        7.10.4 Main Business/Business Overview
    7.11 Pfizer Inc.
    7.12 Pharmis Biofarmaceutica, Lda.
    7.13 Philogen S.p.A.
    7.14 Plexxikon Inc.

8 Metastatic Melanoma Drug Manufacturing Cost, Industrial Chain and Downstream Buyers
    8.1 Metastatic Melanoma Drug Key Raw Materials Analysis
        8.1.1 Key Raw Materials
        8.1.2 Price Trend of Key Raw Materials
        8.1.3 Key Suppliers of Raw Materials
        8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
        8.2.1 Raw Materials
        8.2.2 Labor Cost
        8.2.3 Manufacturing Expenses
    8.3 Metastatic Melanoma Drug Industrial Chain Analysis
    8.4 Downstream Buyers in United States

9 Marketing Strategy Analysis, Distributors and Market Effect Factors
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Distributors in Untied States
    9.3 Market Effect Factors Analysis
        9.3.1 Economic/Political Environmental Change
        9.3.2 Downstream Demand Change
        9.3.3 Technology Progress in Related Industry
        9.3.4 Substitutes Threat

10 Global Metastatic Melanoma Drug Market Forecast
    10.1 Global Metastatic Melanoma Drug Sales, Revenue Forecast (2018-2025)
        10.1.1 Global Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
        10.1.2 Global Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
    10.2 United States Metastatic Melanoma Drug Market Forecast
        10.2.1 United States Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
        10.2.2 United States Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
    10.3 Global Metastatic Melanoma Drug Forecast by Regions
        10.3.1 North America Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
        10.3.2 Europe Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
        10.3.3 Asia-Pacific Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
        10.3.4 South America Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
        10.3.5 Middle East and Africa Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast (2018-2025)
    10.4 Metastatic Melanoma Drug Forecast by Type
        10.4.1 Global Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast by Type (2018-2025)
        10.4.2 United States Metastatic Melanoma Drug Sales (K Pcs) and Revenue (Million USD) Forecast by Type (2018-2025)
    10.5 Metastatic Melanoma Drug Forecast by Application
        10.5.1 Global Metastatic Melanoma Drug Sales (K Pcs) Forecast by Application (2018-2025)
        10.5.2 United States Metastatic Melanoma Drug Sales (K Pcs) Forecast by Application (2018-2025)

11 Research Findings and Conclusion


List of Tables and Figures

    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources
    Figure Metastatic Melanoma Drug Product Picture
    Figure Global Metastatic Melanoma Drug Revenue (Million USD) Status and Outlook (2013-2025)
    Figure United States Metastatic Melanoma Drug Revenue (Million USD) Status and Outlook (2013-2025)
    Figure Product Picture of AGI-134
    Table Major Players of AGI-134
    Figure Global AGI-134 Sales (K Pcs) and Growth Rate (%)(2013-2018)
    Figure Product Picture of ALT-801
    Table Major Players of ALT-801
    Figure Global ALT-801 Sales (K Pcs) and Growth Rate (%)(2013-2018)
    Figure Product Picture of ALT-803
    Table Major Players of ALT-803
    Figure Global ALT-803 Sales (K Pcs) and Growth Rate (%)(2013-2018)
    Figure Product Picture of AMG-232
    Table Major Players of AMG-232
    Figure Global AMG-232 Sales (K Pcs) and Growth Rate (%)(2013-2018)
    Figure Product Picture of Others
    Table Major Players of Others
    Figure Global Others Sales (K Pcs) and Growth Rate (%)(2013-2018)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Comparison by Type (2013, 2017 and 2025)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2013-2018)
    Table Global Metastatic Melanoma Drug Sales Share (%) by Type (2013-2018)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) by Type (2013-2018)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) by Type in 2017
    Table Global Metastatic Melanoma Drug Revenue (Million USD) by Type (2013-2018)
    Table Global Metastatic Melanoma Drug Revenue Share (%) by Type (2013-2018)
    Figure Global Metastatic Melanoma Drug Revenue Share (%) by Type (2013-2018)
    Figure 2017 Global Metastatic Melanoma Drug Revenue Market Share (%) by Type
    Table Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2013-2018)
    Table United States Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Comparison by Type (2013, 2017 and 2025)
    Table United States Metastatic Melanoma Drug Sales (K Pcs) by Type (2013-2018)
    Table United States Metastatic Melanoma Drug Sales Share (%) by Type (2013-2018)
    Figure United States Metastatic Melanoma Drug Sales Market Share (%) by Type (2013-2018)
    Figure United States Metastatic Melanoma Drug Sales Market Share (%) by Type in 2017
    Table United States Metastatic Melanoma Drug Revenue (Million USD) by Type (2013-2018)
    Table United States Metastatic Melanoma Drug Revenue Share (%) by Type (2013-2018)
    Figure United States Metastatic Melanoma Drug Revenue Share (%)by Type (2013-2018)
    Figure 2017 United States Metastatic Melanoma Drug Revenue Market Share (%) by Type
    Table United States Metastatic Melanoma Drug Price (USD/Pcs) by Type (2013-2018)
    Figure Hospital Examples
    Figure Clinic Examples
    Figure Others Examples
    Table Global Metastatic Melanoma Drug Sales (K Pcs) Comparison by Application (2013-2025)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2013-2018)
    Table Global Metastatic Melanoma Drug Sales Share (%) by Application (2013-2018)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) by Application (2013-2018)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) by Application in 2017
    Table United States Metastatic Melanoma Drug Sales (K Pcs) Comparison by Application (2013-2025)
    Table United States Metastatic Melanoma Drug Sales (K Pcs) by Application (2013-2018)
    Table United States Metastatic Melanoma Drug Sales Share (%) by Application (2013-2018)
    Figure United States Metastatic Melanoma Drug Sales Market Share (%) by Application (2013-2018)
    Figure United States Metastatic Melanoma Drug Sales Market Share (%) by Application in 2017
    Table Global Metastatic Melanoma Drug Revenue (Million USD) and CAGR Comparison by Regions (2013-2025)
    Figure North America Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Figure Asia-Pacific Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Figure Europe Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Figure South America Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Figure Middle East and Africa Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Figure United States Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%)(2013-2025)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) by Regions (2013-2018)
    Table Global Metastatic Melanoma Drug Sales Market Share (%) by Regions (2013-2018)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) by Regions (2013-2018)
    Figure 2017 Global Metastatic Melanoma Drug Sales Market Share (%) by Regions
    Figure 2017 United States Metastatic Melanoma Drug Sales Market Share (%) in Global Market
    Table Global Metastatic Melanoma Drug Revenue (Million USD) by Regions (2013-2018)
    Table Global Metastatic Melanoma Drug Revenue Market Share (%) by Regions (2013-2018)
    Figure Global Metastatic Melanoma Drug Revenue Market Share (%) by Regions (2013-2018)
    Figure 2017 Global Metastatic Melanoma Drug Revenue Market Share (%) by Regions
    Figure 2017 United States Metastatic Melanoma Drug Revenue Market Share (%) in Global Market
    Table Global Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table North America Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table Europe Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table Asia-Pacific Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table South America Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table Middle East and Africa Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table United States Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) of Key Players (2013-2018)
    Table Global Metastatic Melanoma Drug Sales Share (%) by Players (2013-2018)
    Figure 2017 Global Metastatic Melanoma Drug Sales Share (%) by Players
    Figure 2018 Global Metastatic Melanoma Drug Sales Share (%) by Players
    Table Global Metastatic Melanoma Drug Revenue (Million USD) by Players (2013-2018)
    Table Global Metastatic Melanoma Drug Revenue Share (%) by Players (2013-2018)
    Table 2017 Global Metastatic Melanoma Drug Revenue Share (%) by Players
    Table 2018 Global Metastatic Melanoma Drug Revenue Share (%) by Players
    Table Global Market Metastatic Melanoma Drug Average Price (USD/Pcs) by Players (2013-2018)
    Table Global Metastatic Melanoma Drug Top Players Manufacturing Base Distribution and Sales Area
    Table Global Metastatic Melanoma Drug Top Players Product Category
    Figure Global Metastatic Melanoma Drug Market Share (%) of Top 3 Players
    Figure Global Metastatic Melanoma Drug Market Share (%) of Top 5 Players
    Table United States Metastatic Melanoma Drug Sales (K Pcs) by Players (2013-2018)
    Table United States Metastatic Melanoma Drug Sales Market Share (%) by Players (2013-2018)
    Figure 2017 United States Metastatic Melanoma Drug Sales Share (%) by Players
    Figure 2018 United States Metastatic Melanoma Drug Sales Share (%) by Players
    Table United States Metastatic Melanoma Drug Revenue (Million USD) by Players (2013-2018)
    Table United States Metastatic Melanoma Drug Revenue Market Share (%) by Players (2013-2018)
    Table 2017 United States Metastatic Melanoma Drug Revenue Share (%) by Players
    Table 2018 United States Metastatic Melanoma Drug Revenue Share (%) by Players
    Table United States Market Metastatic Melanoma Drug Average Price (USD/Pcs) by Players (2013-2018)
    Figure United States Metastatic Melanoma Drug Market Share (%) of Top 3 Players
    Figure United States Metastatic Melanoma Drug Market Share (%) of Top 5 Players
    Table Merck & Co., Inc. Basic Information List
    Table Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Merck & Co., Inc. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Merck & Co., Inc. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Merck & Co., Inc. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Merck KGaA Basic Information List
    Table Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Merck KGaA Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Merck KGaA Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Merck KGaA Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Millennium Pharmaceuticals, Inc. Basic Information List
    Table Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Morphotek, Inc. Basic Information List
    Table Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Morphotek, Inc. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Morphotek, Inc. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Morphotek, Inc. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table NewLink Genetics Corporation Basic Information List
    Table NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure NewLink Genetics Corporation Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure NewLink Genetics Corporation Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure NewLink Genetics Corporation Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Novartis AG Basic Information List
    Table Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Novartis AG Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Novartis AG Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Novartis AG Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Omeros Corporation Basic Information List
    Table Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Omeros Corporation Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Omeros Corporation Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Omeros Corporation Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Oncolytics Biotech Inc. Basic Information List
    Table Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Oncolytics Biotech Inc. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table OncoSec Medical Inc. Basic Information List
    Table OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure OncoSec Medical Inc. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure OncoSec Medical Inc. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure OncoSec Medical Inc. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Ono Pharmaceutical Co., Ltd. Basic Information List
    Table Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2013-2018)
    Figure Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales Growth Rate (2013-2018)
    Figure Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales Global Market Share (%)(2013-2018)
    Figure Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Revenue Global Market Share (%)(2013-2018)
    Table Pfizer Inc. Basic Information List
    Table Pharmis Biofarmaceutica, Lda. Basic Information List
    Table Philogen S.p.A. Basic Information List
    Table Plexxikon Inc. Basic Information List
    Table Sales Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of Metastatic Melanoma Drug
    Figure Metastatic Melanoma Drug Industrial Chain Analysis
    Table Major Buyers of Metastatic Melanoma Drug
    Table Distributors/Traders List
    Figure Global Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure Global Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
    Figure United States Metastatic Melanoma DrugMetastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure United States Metastatic Melanoma Drug Revenue (Million USD) and Growth Rate (%) Forecast (2018-2025)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) Forecast by Regions (2018-2025)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) Forecast by Regions (2018-2025)
    Figure North America Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure North America Metastatic Melanoma Drug Revenue and Growth Rate (%) Forecast (2018-2025)
    Figure Europe Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure Europe Metastatic Melanoma Drug Revenue and Growth Rate (%) Forecast (2018-2025)
    Figure Asia-Pacific Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure Asia-Pacific Metastatic Melanoma Drug Revenue and Growth Rate (%) Forecast (2018-2025)
    Figure South America Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure South America Metastatic Melanoma Drug Revenue and Growth Rate (%) Forecast (2018-2025)
    Figure Middle East and Africa Metastatic Melanoma Drug Sales (K Pcs) and Growth Rate (%) Forecast (2018-2025)
    Figure Middle East and Africa Metastatic Melanoma Drug Revenue and Growth Rate (%) Forecast (2018-2025)
    Table Global Metastatic Melanoma Drug Sales (Million USD) Forecast by Type (2018-2025)
    Figure Global Metastatic Melanoma Drug Sales Market Share (%) Forecast by Type (2018-2025)
    Table Global Metastatic Melanoma Drug Revenue (Million USD) Forecast by Type (2018-2025)
    Figure Global Metastatic Melanoma Drug Revenue Market Share (%) Forecast by Type (2018-2025)
    Table United States Metastatic Melanoma Drug Sales (Million USD) Forecast by Type (2018-2025)
    Figure United States Metastatic Melanoma Drug Sales Market Share (%) Forecast by Type (2018-2025)
    Table United States Metastatic Melanoma Drug Revenue (Million USD) Forecast by Type (2018-2025)
    Figure United States Metastatic Melanoma Drug Revenue Market Share (%) Forecast by Type (2018-2025)
    Table Global Metastatic Melanoma Drug Sales (K Pcs) Forecast by Application (2018-2025)
    Figure Global Metastatic Melanoma Drug Sales Forecast by Application (2018-2025)
    Table United States Metastatic Melanoma Drug Sales (K Pcs) Forecast by Application (2018-2025)
    Figure United States Metastatic Melanoma Drug Sales Forecast by Application (2018-2025)

Request sample If you need any reports sample, just let us know.